{"disease":{"id":"b-cell-chronic-lymphocytic-leukemia-in-relapse-diagnosis","name":"b cell chronic lymphocytic leukemia in relapse diagnosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03185494","title":"Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03755947","title":"Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Grupo Cooperativo de Hemopatías Malignas","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}